Trial
NCT04266730
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
—
Condition
Squamous Cell Lung Cancer
Intervention
PANDA-VAC
Why stopped
Not stated
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-23